Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements
Launched by DAACRO · May 3, 2021
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Background:
Hydroxytyrosol is a phenolic phytochemical naturally occurring in olives with potential antioxidant, anti-inflammatory, and health benefits mainly related with cardiovascular diseases \[for review see Covas et al., 2015\]. OliPhenolia® bitter and OliPhenolia® are two food supplements resulting from the liquid by-product generated during olive oil production, that are rich in olive polyphenols, mainly hydroxytyrosol. Hydroxytyrosol and its derivatives (tyrosol and oleuropein) are present in higher levels in the watery extracts from olives when compared with the oil fraction.
Mo...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Self-reported healthy men aged 21-50,
- • subject has an adequate understanding of the study and signs the informed consent to participate in the study,
- • willingness to follow dietary and physical activity restrictions during study participation,
- • body mass index range: \>18.5 and \<29.9 kg/m2.
- Exclusion Criteria:
- • Any known allergies to IPs (olives and their derivates),
- • any acute and chronic diseases (e.g. diagnosis of diabetes mellitus, hypertension, dyslipidemia or other cardiometabolic disorders, diagnosed hepatic, renal, or cardiovascular disease),
- • any kind of eating disorders,
- • not fluent in German,
- • any previous (last 14 days prior to screening) and any ongoing pharmacological therapy (e.g. any medication, vaccination, infusion),
- • any intake of nutritional supplements,
- • any known addiction to drugs and/or alcohol,
- • smoker,
- • Investigator or physician doubts truthfulness of self-reported health information.
About Daacro
daacro is a leading clinical trial management organization dedicated to advancing medical research through innovative and efficient trial solutions. With a focus on patient-centric approaches, daacro partners with pharmaceutical, biotechnology, and medical device companies to streamline the clinical development process. Leveraging a team of experienced professionals and state-of-the-art technology, daacro ensures the highest standards of quality and regulatory compliance while fostering collaboration to accelerate the delivery of new therapies to market. Their commitment to excellence and transparency positions daacro as a trusted partner in the evolving landscape of clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trier, Rhineland Palatinate, Germany
Patients applied
Trial Officials
Juliane Hellhammer, PhD
Principal Investigator
Daacro
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials